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BACKGROUND
Thrombolytic therapy for acute ischemic stroke with a lower-than-standard dose of intrave-
nous alteplase may improve recovery along with a reduced risk of intracerebral hemorrhage.
METHODS
Using a 2-by-2 quasi-factorial open-label design, we randomly assigned 3310 patients who were 
eligible for thrombolytic therapy (median age, 67 years; 63% Asian) to low-dose intravenous 
alteplase (0.6 mg per kilogram of body weight) or the standard dose (0.9 mg per kilogram); 
patients underwent randomization within 4.5 hours after the onset of stroke. The primary 
objective was to determine whether the low dose would be noninferior to the standard dose 
with respect to the primary outcome of death or disability at 90 days, which was defined by 
scores of 2 to 6 on the modified Rankin scale (range, 0 [no symptoms] to 6 [death]). Second-
ary objectives were to determine whether the low dose would be superior to the standard dose 
with respect to centrally adjudicated symptomatic intracerebral hemorrhage and whether 
the low dose would be noninferior in an ordinal analysis of modified Rankin scale scores 
(testing for an improvement in the distribution of scores). The trial included 935 patients who 
were also randomly assigned to intensive or guideline-recommended blood-pressure control.
RESULTS
The primary outcome occurred in 855 of 1607 participants (53.2%) in the low-dose group 
and in 817 of 1599 participants (51.1%) in the standard-dose group (odds ratio, 1.09; 95% 
confidence interval [CI], 0.95 to 1.25; the upper boundary exceeded the noninferiority mar-
gin of 1.14; P = 0.51 for noninferiority). Low-dose alteplase was noninferior in the ordinal 
analysis of modified Rankin scale scores (unadjusted common odds ratio, 1.00; 95% CI, 
0.89 to 1.13; P = 0.04 for noninferiority). Major symptomatic intracerebral hemorrhage oc-
curred in 1.0% of the participants in the low-dose group and in 2.1% of the participants in 
the standard-dose group (P = 0.01); fatal events occurred within 7 days in 0.5% and 1.5%, 
respectively (P = 0.01). Mortality at 90 days did not differ significantly between the two 
groups (8.5% and 10.3%, respectively; P = 0.07).
CONCLUSIONS
This trial involving predominantly Asian patients with acute ischemic stroke did not show 
the noninferiority of low-dose alteplase to standard-dose alteplase with respect to death 
and disability at 90 days. There were significantly fewer symptomatic intracerebral hemor-
rhages with low-dose alteplase. (Funded by the National Health and Medical Research 
Council of Australia and others; ENCHANTED ClinicalTrials.gov number, NCT01422616.)
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Thrombolytic therapy with intra-venous alteplase (recombinant tissue-type plasminogen activator) at a dose of 0.9 mg 
per kilogram of body weight is an effective treat-
ment for acute ischemic stroke, despite increasing 
the risk of intracerebral hemorrhage.1-3 How-
ever, the Japanese drug safety authority has ap-
proved the use of alteplase at a dose of 0.6 mg 
per kilogram after an uncontrolled, open-label 
study showed that this dose resulted in equivalent 
clinical outcomes and a lower risk of intracere-
bral hemorrhage than that reported in published 
studies in which the 0.9-mg-per-kilogram dose 
was used.4 Other registry studies in Asia5-11 have 
shown inconsistent results, but a high risk of 
symptomatic intracerebral hemorrhage was ob-
served among Asian patients treated with 0.9 mg 
of alteplase per kilogram in the United States.12 
Differing perceived risks of intracerebral hemor-
rhage and treatment affordability have led to varia-
tions in the doses of intravenous alteplase used to 
treat patients with acute ischemic stroke in Asia.8-11
The Enhanced Control of Hypertension and 
Thrombolysis Stroke Study (ENCHANTED) was 
designed to compare low-dose with standard-
dose intravenous alteplase in patients with acute 
ischemic stroke. Using a quasi-factorial design, 
we are also assessing the effects of early inten-
sive lowering of blood pressure as compared 
with guideline-recommended management in pa-
tients with elevated blood pressure; this part of 
the trial is scheduled to be completed in 2018. 
We report the results of the alteplase part of the 
trial, which was completed in December 2015.
Me thods
Trial Design and Oversight
In an international, multicenter, prospective, ran-
domized, open-label trial with blinded outcome 
evaluation, two doses of intravenous alteplase 
were compared in patients with an acute ische-
mic stroke who were eligible for thrombolytic 
therapy; administration of the drug was com-
menced within 4.5 hours after the onset of the 
stroke. Patients with elevated systolic blood 
pressure (range, 150 to 220 mm Hg) could also 
be randomly assigned to early and intensive low-
ering of blood pressure (target systolic blood pres-
sure <140 mm Hg within 1 hour) or conventional 
guideline-directed management of blood pressure 
(target systolic blood pressure <180 mm Hg) with 
the use of locally available intravenous agents.
Details of the design and statistical analysis 
plan of the trial have been published previously.13,14 
An international steering committee, whose mem-
bers designed the trial with an advisory commit-
tee, was responsible for the conduct and report-
ing of the trial. The George Institute for Global 
Health coordinated the trial, managed the data-
base, and performed the analyses. The study drug 
used (alteplase) was that available for routine use 
at clinical centers; there was no commercial input 
into any aspect of the trial. The first author wrote 
the first and subsequent drafts of the manuscript. 
All the authors commented on drafts of the manu-
script, approved the decision to submit the manu-
script for publication, and vouch for the accuracy 
and completeness of the data and for the fidelity 
of this report to the trial protocol (available with 
the full text of this article at NEJM.org).
The trial protocol was approved by all appro-
priate regulatory authorities and ethics commit-
tees at the participating centers. All participants, 
or an approved surrogate for those who were too 
unwell to comprehend the information, provided 
written informed consent. Details of the moni-
toring procedures are provided in the Supple-
mentary Appendix (available at NEJM.org).
Patients and Procedures
Patients were recruited at 111 clinical centers in 
13 countries. Patients were eligible if they were 
18 years of age or older, had an acute ischemic 
stroke, and met guideline-recommended criteria 
for treatment with intravenous alteplase. For de-
tails of the inclusion and exclusion criteria, see 
the Supplementary Appendix.
After confirmation of patient eligibility, ran-
domization was performed centrally with the use 
of a minimization algorithm according to center, 
time from stroke onset (<3 vs. ≥3 hours), and 
severity of neurologic impairment (score of <10 
vs. ≥10 on the National Institutes of Health Stroke 
Scale [NIHSS]; range, 0 to 42, with higher scores 
indicating greater severity of stroke). Participants 
were randomly assigned to receive either a stan-
dard dose of intravenous alteplase (0.9 mg per 
kilogram of estimated, or measured, body weight; 
10% as a bolus and 90% as an infusion over a 
period of 60 minutes; maximum dose, 90 mg) or 
a low dose (0.6 mg per kilogram, 15% as a bolus 
and 85% as an infusion over a period of 60 min-
utes; maximum dose, 60 mg), to be commenced 
within 4.5 hours after symptom onset. Concomi-
tant therapy followed national practice guidelines, 
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including the use of endovascular thrombectomy 
devices, where approved.
Demographic and clinical data were obtained 
at the time of randomization. Follow-up data 
were obtained at 24 and 72 hours (including re-
peat NIHSS scores and measured body weight) 
and at 7 days (or hospital discharge, if sooner), 
28 days, and 90 days, unless death occurred ear-
lier. The 28-day and 90-day evaluations were con-
ducted in person or by telephone, by trained and 
certified staff who remained unaware of the ran-
domized treatment assignments. Brain imaging 
was performed at trial entry and at 24 hours, and 
additionally if clinically indicated, and was ana-
lyzed centrally for any hemorrhage by expert 
assessors who were unaware of the treatment 
assignments (see the Supplementary Appendix).
Outcomes
The prespecified primary outcome was the com-
bined end point of death or disability at 90 days, 
which was defined by scores of 2 to 6 on the 
modified Rankin scale,15 a global seven-level 
measure of functioning in which scores of 0 or 
1 indicate a good outcome with no or minimal 
neurologic symptoms, scores of 2 to 5 indicate a 
poor outcome with increasing degree of disabil-
ity, and 6 indicates death. The key secondary 
outcome, which was also designated as a safety 
outcome, was intracerebral hemorrhage, defined 
according to criteria from a number of other 
studies (see the Supplementary Appendix); the 
main definition of intracerebral hemorrhage that 
we used was the definition in the Safe Imple-
mentation of Thrombolysis in Stroke-Monitoring 
Study (SITS-MOST)16: a large local or remote 
parenchymal pattern (>30% of the infarcted area 
affected by hemorrhage, with mass effect or ex-
tension outside the infarct) and neurologic dete-
rioration from baseline (increase of ≥4 points in 
the NIHSS score) or death within 36 hours. This 
definition was finalized and described in the 
statistical analysis plan of our trial after publica-
tion of the original protocol.
Other secondary efficacy outcomes were the 
distribution of modified Rankin scale scores at 
90 days,17 major disability (modified Rankin scale 
score >2) at 90 days, deaths at 7 days and 90 days, 
neurologic deterioration (increase of ≥4 points 
in the NIHSS score) during the 72 hours after 
randomization, death and neurologic deteriora-
tion (increase of ≥4 points in the NIHSS score) 
during the 72 hours after randomization, health-
related quality of life on the EuroQoL Group 
5-Dimension Self-Report Questionnaire (EQ-5D; 
summary health utility scores range from −0.109 
to 1, with higher scores indicating better health)18 
at 90 days (for details on scoring, see the Supple-
mentary Appendix), length of initial hospital stay, 
recurrent acute myocardial infarction and recurrent 
ischemic stroke, admission to a long-term residen-
tial care facility at 90 days, and use of health ser-
vices (for economic analyses that have not yet been 
conducted). Prespecified safety outcomes were 
all serious adverse events reported until trial com-
pletion. Tertiary outcomes included all-cause mor-
tality, place of death, trends in modified Rankin 
scale scores during follow-up, length of stay in 
the intensive care unit (ICU), rate of thrombec-
tomy, and individual items of the EQ-5D.
Statistical Analysis
We designed the trial to assess the effects of two 
treatment variables — alteplase dose and inten-
sity of blood-pressure control — on clinical out-
comes, accounting for their potential interac-
tion.14 Differential patient recruitment resulted in 
the part of the trial dealing with alteplase dose 
being completed faster than the part dealing with 
intensity of blood-pressure control. For the pri-
mary analysis, we used an unadjusted logistic-
regression model to test whether low-dose alte-
plase was noninferior to the standard dose. To 
satisfy the noninferiority hypothesis, the upper 
boundary of the 95% confidence interval for the 
odds ratio of the outcome with low-dose alte-
plase as compared with standard-dose alteplase 
had to fall below a margin of 1.14; this noninfe-
riority margin was derived from a Cochrane meta-
analyses of alteplase trials with effects on poor 
outcomes reported.19,20 We estimated that a sam-
ple size of 3300 patients would provide at least 
90% power to evaluate noninferiority, assuming 
5% dropout and potential negative interaction be-
tween intensive blood-pressure control and low-
dose alteplase, and would also provide at least 80% 
power to detect superiority of low-dose alteplase 
in achieving a 40% lower risk of symptomatic 
intracerebral hemorrhage than that with standard-
dose alteplase, with 5% dropout. Consistency of 
treatment effect across 10 prespecified subgroups 
was assessed through tests for interaction.
A secondary efficacy analysis was a compari-
son of ordinal scores on the modified Rankin 
scale to test for the noninferiority of the low 
dose to the standard dose with the use of ordi-
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Variable
Low-Dose 
 Alteplase 
(N = 1654)
Standard-Dose 
 Alteplase 
(N = 1643)
Age — yr
Median 68 67
IQR 58–76 58–76
Female sex — no. (%) 634 (38.3) 614 (37.4)
Region of recruitment — no. (%)
China 708 (42.8) 711 (43.3)
United Kingdom, continental Europe, or Australia 445 (26.9) 439 (26.7)
Asia, other than China 336 (20.3) 334 (20.3)
South America 165 (10.0) 159 (9.7)
Asian race — no./total no. (%)† 1043/1651 (63.2) 1036/1640 (63.2)
Medical history — no./total no. (%)‡
Hypertension 1031/1648 (62.6) 1034/1640 (63.0)
Any stroke 287/1654 (17.4) 302/1643 (18.4)
Coronary artery disease 256/1648 (15.5) 223/1640 (13.6)
Atrial fibrillation 330/1645 (20.1) 306/1640 (18.7)
Diabetes mellitus 325/1648 (19.7) 321/1640 (19.6)
Hypercholesterolemia 297/1648 (18.0) 258/1640 (15.7)
Current cigarette use 377/1646 (22.9) 393/1638 (24.0)
Modified Rankin scale score of 0 before stroke§ 1349/1647 (81.9) 1325/1639 (80.8)
Use of antihypertensive agent 755/1648 (45.8) 743/1640 (45.3)
Use of statin or other lipid-lowering agent 333/1646 (20.2) 282/1638 (17.2)
Use of aspirin or other antiplatelet agent 407/1647 (24.7) 345/1638 (21.1)
Warfarin anticoagulation 48/1647 (2.9) 34/1638 (2.1)
Blood pressure — mm Hg
Systolic 149±20 150±20
Diastolic 84±13 85±13
NIHSS score — median (IQR)¶ 8 (5–14) 8 (5–14)
Signs of cerebral ischemia on brain imaging — no./total no. (%)‖ 388/1648 (23.5) 383/1640 (23.4)
Proximal vessel occlusion on CTA or MRA — no./total no. (%)‖ 258/1622 (15.9) 248/1624 (15.3)
Final diagnosis at time of hospital discharge — no./total no. (%)**
Nonstroke diagnosis 50/1625 (3.1) 47/1609 (2.9)
Large-artery occlusion due to clinically significant atheroma 622/1625 (38.3) 648/1609 (40.3)
Small-vessel or perforator lacunar disease 334/1625 (20.6) 339/1609 (21.1)
Cardioembolism 324/1625 (19.9) 317/1609 (19.7)
Dissection 14/1625 (0.9) 11/1609 (0.7)
Other or uncertain cause of stroke 281/1625 (17.3) 247/1609 (15.4)
Time from stroke onset to alteplase administration — min††
Median 170 170
IQR 125–218 127–219
Estimated body weight before alteplase administration — kg 69.6±14.4 69.9±14.4
Table 1. Characteristics of the Patients at Baseline and Their Treatment.*
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nal logistic regression, after the assumption of 
proportionality of the odds was confirmed in a 
likelihood-ratio test.17 A new assumption-free 
approach21 was used to confirm the conclusion. 
We also performed secondary analyses of the 
primary outcome with adjustment for minimiza-
tion and key prognostic covariates14, as well as 
secondary analyses in the per-protocol popula-
tion according to criteria outlined in the Supple-
mentary Appendix. Multiple imputation was to 
be used if more than 10% of observations were 
missing. An independent data and safety moni-
toring board monitored the trial progress and 
safety with the use of formal stopping bound-
aries. For ease of interpretation, all reported 
P values for noninferiority are multiplied by 2 so 
that an alpha of 0.05 can be used in analyses. 
The other P values (those for superiority) are 
two-sided. All P values were prespecified not to 
be adjusted. SAS software, version 9.3 (SAS Insti-
tute), was used for analyses.
R esult s
Patients
From March 2012 through August 2015, a total 
of 3310 of the 69,325 patients who were screened 
underwent randomization (Fig. S1 and Table S1 
in the Supplementary Appendix); 1654 patients 
were assigned to low-dose alteplase and 1643 to 
standard-dose alteplase. There were no signifi-
cant differences between the low-dose group and 
the standard-dose group in baseline demograph-
ic and clinical characteristics (Table 1, and Table 
S2 in the Supplementary Appendix), nor in the 
number of patients assigned to each of the 
blood-pressure-lowering groups. The median age 
of the patients was 67 years (14% were ≥80 years 
of age), and 38% were women. Approximately 
two thirds of the patients were Asian, and 43% 
were recruited from China. The median NIHSS 
score before treatment was 8 (range, 0 to 42; 
interquartile range, 5 to 14), and the median 
time from stroke onset to randomization was 
2.7 hours (interquartile range, 2.0 to 3.5).
Interventions
In both groups, the mean time from the onset 
of stroke to administration of alteplase was 170 
minutes; the mean dose of alteplase adminis-
tered as an infusion was 35.5 mg in the low-dose 
group and 56.0 mg in the standard-dose group 
(P<0.001) (Table 1). The distribution of dosing 
and the protocol violations are outlined in Figure 
Variable
Low-Dose 
 Alteplase 
(N = 1654)
Standard-Dose 
 Alteplase 
(N = 1643)
Any alteplase given to patients — no. (%) 1628 (98.4) 1617 (98.4)
Bolus dose — mg 6.2±1.2 6.3±2.1
Infusion dose — mg 35.5±7.3 56.0±11.3
Concurrent inclusion in part of trial dealing with blood-pressure 
 control — no. (%)
460 (27.8) 475 (28.9)
Assigned to intensive blood-pressure lowering 224 (13.5) 232 (14.1)
Assigned to standard blood-pressure lowering 236 (14.3) 243 (14.8)
*  Plus–minus values are means ±SD. There were no significant differences between trial groups in the characteristics 
listed, except in the administered dose of alteplase as a bolus (P = 0.05) and as an infusion (P<0.001). CTA denotes 
computed tomographic angiography, IQR interquartile range, and MRA magnetic resonance angiography.
†  Race was self-reported.
‡  Medical history was based on self-report, with the exception of the presence of atrial fibrillation, which was based on 
findings on electrocardiography performed at the time of presentation.
§  The modified Rankin scale evaluates global disability; scores range from 0 (no symptoms) to 6 (death).
¶  Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating 
more severe neurologic deficits. Scores ranged from 0 to 40 in the low-dose group and from 0 to 42 in the standard-
dose group.
‖  This finding was reported by clinician investigators.
**  Diagnoses were determined by clinician investigators.
††  Times ranged from 28 to 1673 minutes (0.47 to 27.88 hours) in the low-dose group and from 11 to 1678 minutes 
(0.18 to 27.97 hours) in the standard-dose group.
Table 1. (Continued.)
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S2 and Tables S3 and S4 in the Supplementary 
Appendix. Postrandomization management, in-
cluding endovascular thrombectomy and rates of 
recanalization, was similar in the two groups 
during the first 7 days (Table S5 in the Supple-
mentary Appendix). Outcome at 90 days was as-
sessed by telephone in 84.6% of the patients in the 
low-dose group and in 83.6% of the patients in 
the standard-dose group; the rest of the patients 
were assessed by in-person examination. The 
sources of information for the modified Rankin 
scale scores were balanced between the groups 
(Table S6 in the Supplementary Appendix).
Blood-Pressure Control
In the part of the trial dealing with blood-pres-
sure control that included 935 patients with 
elevated systolic blood pressure (range, 150 to 
220 mm Hg), 224 patients in the low-dose group 
(13.5%) and 232 in the standard-dose group 
(14.1%) were assigned to rapid blood-pressure 
reduction. In both alteplase dose groups, the 
mean systolic blood pressure levels were signifi-
cantly lower, by 7 to 9 mm Hg, with intensive 
blood-pressure control than with standard blood-
pressure management at 1 hour and 6 hours 
after randomization (Table S7 in the Supplemen-
tary Appendix).
Primary Outcome
Scores on the modified Rankin scale for assess-
ment of the primary outcome could not be ob-
tained, owing to withdrawal of consent or loss 
to follow-up, in 47 of the patients assigned to 
low-dose alteplase and 44 assigned to standard-
dose alteplase (Fig. S1 in the Supplementary 
Appendix). In the modified intention-to-treat 
analysis, the primary outcome (scores of 2 to 
6 on the modified Rankin scale) occurred in 855 
of 1607 patients (53.2%) in the low-dose group 
and in 817 of 1599 patients (51.1%) in the stan-
dard-dose group (odds ratio, 1.09; 95% confi-
dence interval [CI], 0.95 to 1.25; the upper 
boundary of the 95% confidence interval ex-
ceeded the prespecified boundary for noninferi-
ority of 1.14; one-sided P = 0.51 for noninferiori-
ty) (Table 2, and Fig. S3 in the Supplementary 
Appendix). In an adjusted analysis of the inten-
tion-to-treat population, the rate was 53.3% in 
the low-dose group and 50.9% in the standard-
dose group (odds ratio, 1.13; 95% CI, 0.97 to 
1.31; P = 0.88 for noninferiority); in an adjusted 
analysis in the per-protocol population, the rates 
were 53.5% and 51.3%, respectively (odds ratio, 
1.13; 95% CI, 0.96 to 1.32; one-sided P = 0.89 for 
noninferiority). There was no heterogeneity of 
effect between patients who began alteplase 
treatment less than 3 hours after stroke onset 
and those who began treatment 3 or more hours 
after stroke onset (Fig. S5 in the Supplementary 
Appendix), and there was no significant interac-
tion between intensity of blood-pressure lower-
ing and alteplase dose (P = 0.29).
Secondary Outcomes
In an unadjusted ordinal analysis of the distribu-
tion of modified Rankin scale scores in the two 
groups, the odds ratio with low-dose alteplase as 
compared with standard-dose alteplase was 1.00 
(95% CI, 0.89 to 1.13; P = 0.04 for noninferiority) 
(Table 2). The assumption-free, adjusted, and 
per-protocol alternative approaches were consis-
tent in showing no significant difference in the 
treatment effect for overall functional outcome 
on the modified Rankin scale between doses of 
alteplase (Fig. 1, and Figs. S3, S4, and S6 and 
Tables S8, S9, and S10 in the Supplementary Ap-
pendix).
Major symptomatic intracerebral hemorrhage 
according to SITS-MOST criteria occurred in 17 
of 1654 patients (1.0%) in the low-dose group 
and in 35 of 1643 patients (2.1%) in the stan-
dard-dose group (odds ratio, 0.48; 95% CI, 0.27 
to 0.86; P = 0.01) (Table 2). There was no signifi-
cant interaction between intensive blood-pressure 
lowering and alteplase dose group with respect 
to the risk of major symptomatic intracerebral 
hemorrhage (P = 0.71). Symptomatic intracerebral 
hemorrhage according to other criteria also oc-
curred significantly less frequently in the low-
dose group than in the standard-dose group 
(Table 2, and Fig. S7 in the Supplementary Ap-
pendix); for example, the rate of fatal events 
within 7 days was 0.5% in the low-dose group 
and 1.5% in the standard-dose group (odds ra-
tio, 0.37; 95% CI, 0.17 to 0.80; P = 0.01). There 
was no heterogeneity in the effect of alteplase 
dose on the risk of symptomatic intracerebral 
hemorrhage between Asians and non-Asians (Fig. 
S8 in the Supplementary Appendix).
Mortality at 7 days was 3.6% in the low-dose 
group versus 5.3% in the standard-dose group 
(odds ratio, 0.67; 95% CI, 0.48 to 0.94; P = 0.02), 
and mortality at 90 days was 8.5% versus 10.3% 
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(odds ratio, 0.80; 95% CI, 0.63 to 1.01; P = 0.07) 
(Fig. S9 and Table S11 in the Supplementary Ap-
pendix). No significant between-group differ-
ences were evident in other secondary outcomes 
(Table 2). Other outcomes, including length of 
stay in the ICU, recurrent vascular events, and 
individual components of the EQ-5D, are not 
reported here.
Subgroup Analyses
There was no significant heterogeneity of treat-
ment effect on the primary outcome across pre-
specified subgroups (Fig. 2). The interaction 
between alteplase dose and aspirin or other an-
tiplatelet therapy was not significant (P = 0.05); 
however, this interaction was significant (P = 0.02) 
in a post hoc unadjusted ordinal analysis of 
modified Rankin scale scores (Fig. S10 in the 
Supplementary Appendix). Post hoc analyses 
showed consistency in the effect of alteplase 
dose on death at 90 days across subgroups and 
no clear relation with baseline NIHSS score (Fig. 
S11 and S12 in the Supplementary Appendix).
Safety
There was no significant difference between the 
low-dose group and the standard-dose group in 
the overall reported rate of serious adverse 
events, which occurred in 25.1% and 27.3% of 
the patients, respectively (P = 0.16). However, 
significantly fewer patients in the low-dose al-
teplase group than in the standard-dose al-
teplase group had (unadjudicated) fatal cerebral 
hemorrhage events (1.3% vs. 2.5%, P = 0.02). All 
serious adverse events are listed in Table S12 in 
the Supplementary Appendix.
Discussion
In patients with acute ischemic stroke who met 
guideline-recommended criteria for thrombolyt-
ic reperfusion treatment, a dose of 0.6 mg of 
alteplase per kilogram was not shown to be 
noninferior to a dose of 0.9 mg of alteplase per 
kilogram with respect to the primary outcome 
of death or disability at 90 days. Our trial was 
driven by concern about high risks of intracere-
bral hemorrhage with alteplase, particularly 
among Asians, because preliminary studies have 
had differing results with respect to the effec-
tiveness and risks of this treatment.8,11 Using 
several definitions of symptomatic intracerebral 
hemorrhage,22 we observed fewer clinically im-
portant cases in the group assigned to low-dose 
alteplase than in the group assigned to stan-
dard-dose alteplase, and the difference in risk 
was consistent in Asians and non-Asians.
The distribution of modified Rankin scale 
scores in the two groups at 90 days indicates 
that the lower rate of death with low-dose al-
teplase than with standard-dose alteplase was 
accompanied by more patients surviving with 
mild to moderately severe grades of residual dis-
ability. There was no heterogeneity of treatment 
effect on the primary outcome in prespecified 
subgroups, but these analyses had low statistical 
Figure 1. Functional Outcomes at 90 Days, According to Score on the Modified Rankin Scale.
Shown is the raw distribution of scores on the modified Rankin scale at 90 days in the group that received a low 
dose of alteplase (0.6 mg per kilogram of body weight) and the group that received the standard dose of alteplase 
(0.9 mg per kilogram). Scores on the modified Rankin scale range from 0 to 6, with 0 indicating no symptoms, 1 
symptoms without clinically significant disability, 2 slight disability, 3 moderate disability, 4 moderately severe dis-
ability, 5 severe disability, and 6 death.
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power. One fifth of our trial population were 
receiving antiplatelet therapy. Previous studies 
have shown an increased risk of intracerebral 
hemorrhage with standard-dose alteplase among 
patients receiving antiplatelet therapy.23,24 In our 
prespecified analysis, there was no significant 
interaction between alteplase dose and antiplate-
let treatment with respect to a poor outcome; 
however, the interaction was significant in a 
post hoc ordinal analysis of modified Rankin 
scale scores. The ongoing part of this trial is 
testing the effectiveness of intensive and early 
reduction of elevated systolic blood pressure on 
outcomes in patients with ischemic stroke. 
Analyses did not indicate any significant interac-
tion between early intensive blood-pressure low-
ering and alteplase dose.
Efforts to minimize reporting biases in this 
Figure 2. Effects of Low-Dose Alteplase as Compared with Standard-Dose Alteplase on the Primary Efficacy Outcome, According to 
 Prespecified Subgroups.
The primary efficacy outcome was death or disability at 90 days, defined by scores of 2 to 6 on the modified Rankin scale (range,  
0 [no symptoms] to 6 [death]). Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores 
 indicating more severe neurologic deficits. For subcategories, black squares represent point estimates (with the area of the square 
 proportional to the number of events), and horizontal lines represent 95% confidence intervals. For systolic blood pressure and NIHSS 
score, values are equal to or above the median of distribution versus below the median of distribution. CT denotes computed tomog-
raphy.
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open-label trial included the measurement of 
body weight, blinded central adjudication of in-
tracerebral hemorrhage, and blinded evaluation 
of clinical outcomes with the use of established 
criteria. Imprecision in estimates of the treat-
ment effect may have arisen from interobserver 
variability in determining the scores on the 
modified Rankin scale,15,25 which was adminis-
tered principally by telephone. Analysis of the 
net change in functional outcome was based on 
equal weights assigned to each score (0 through 
6) on the modified Rankin scale, but patient and 
provider assessments can vary across health 
transitions,26 and functional recovery can contin-
ue beyond 90 days.27 In our trial, selection bias 
was due to the inclusion of patients who had a 
predominantly mild severity of neurologic im-
pairment and who were treated at a later time 
point after symptom onset than in other trials1,3,4 
and than in quality-assurance studies12,16,28 of the 
use of alteplase in patients with acute ischemic 
stroke. The high percentage of Asian participants 
and concurrent intensive blood-pressure control 
in some patients may also raise concerns about 
generalizability, despite the finding that there 
were no significant interactions observed be-
tween Asians and non-Asians, nor with intensity 
of blood-pressure control.
In conclusion, in a group of predominantly 
Asian patients with acute ischemic stroke who 
were eligible for thrombolysis reperfusion ther-
apy, a dose of alteplase of 0.6 mg per kilogram 
was not shown to be noninferior to the standard 
dose of 0.9 mg per kilogram with respect to the 
primary outcome of death and disability. Fewer 
patients treated with low-dose alteplase than 
with standard-dose alteplase (1% vs. 2%) had the 
secondary outcome of symptomatic intracerebral 
hemorrhage.
Presented at the European Stroke Organization Conference, 
Barcelona, May 10–12, 2016.
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